Incorporation of salmon calcitonin-loaded poly(lactide- co -glycolide) (PLGA) microspheres into calcium phosphate bone cement and the biocompatibility evaluation in vitro

Abstract

Slow tissue ingrowth is the major drawback for the use of calcium phosphate cements; to address the issue, salmon calcitonin–loaded biodegradable poly(lactide-co-glycolide) microspheres were incorporated into calcium phosphate cement in this study. The effects of poly(lactide-co-glycolide) weight ratio on the mechanical strength, self-setting properties, and salmon calcitonin release ability of calcium phosphate cement were systematically investigated. The in vitro degradation behavior and the cumulative mass loss (%) of the composite during incubation in phosphate-buffered saline were studied. The release of salmon calcitonin was sustained for at least 35 days, and the release rate can be tailored by adjusting the ratio of PLGA. The scanning electron microscopic images of the composites after incubation for 48 days indicated that the poly(lactide-co-glycolide) degraded completely and formed a porous structure in the calcium phosphate cement. An in vitro cell culture of the calcium phosphate cement/salmon calcitonin–poly(lactide-co-glycolide) cement provided more biocompatible than calcium phosphate cement. This composite possesses the basic performance for clinical needs, and it has potential use for treating osteoporosis and accelerating bone repair.

Keywords

calcium phosphate cement/salmon calcitonin–poly(lactide-co-glycolide) composite calcium phosphate cement poly(lactide-co-glycolide) microsphere salmon calcitonin in vitro degradation cell compatibility control release

Get full access to this article

View all access options for this article.

References

LeGeros

. Biodegradation and bioresorption of calcium phosphate ceramics. Clin Mater 1993; 14: 65–88.

Best

Porter

Thian

. Bioceramics: past, present and for the future. J Eur Cer Soc 2008; 28: 1319–1327.

Ducheyne

Qiu

. Bioactive ceramics: the effect of surface reactivity on bone formation and bone cell function. Biomaterials 1999; 20: 2287–2303.

Jarcho

. Calcium phosphate ceramics as hard tissue prosthetics. Clin Orthop Relat Res 1981; 157: 259–278.

Laurencin

Ambrosio

Borden

. Tissue engineering: orthopedic applications. Annu Rev Biomed Eng 1999; 1: 19–46.

Yuan

de Bruijn

. Tissue responses of calcium phosphate cement: a study in dogs. Biomaterials 2000; 21: 1283–1290.

Vallet-Regi

Gonzalez-Calbet

. Calcium phosphates as substitution of bone tissues. Prog Solid State Chemistry 2004; 32: 1–31.

Del Real

Wolke

Vallet-Regi

. A new method to produce macropores in calcium phosphate cements. Biomaterials 2002; 23: 3673–3680.

Kai

Zhu

. Addition of sodium hyaluronate and the effect on performance of the injectable calcium phosphate cement. J Mater Sci Mater Med 2009; 20: 1595–1602.

10.

Mino-Farina

Munoz-Guzon

Lopez-Pena

. Quantitative analysis of the resorption and osteoconduction of a macroporous calcium phosphate bone cement for the repair of a critical size defect in the femoral condyle. Vet J 2009; 179: 264–272.

11.

Weir

Burguera

. Injectable and macroporous calcium phosphate cement scaffold. Biomaterials 2006; 27: 4279–4287.

12.

Link

van den Dolder

Jurgens

. Mechanical evaluation of implanted calcium phosphate cement incorporated with PLGA microparticles. Biomaterials 2006; 27: 4941–4947.

13.

Ruhé

Hedberg

Padron

. Biocompatibility and degradation of poly(DL-lactic-co-glycolic acid)/calcium phosphate cement composites. J Biomed Mater Res A 2005; 74: 533–544.

14.

Feng

Guolin

Yuan

. Role of macropore size in the mechanical properties and in vitro degradation of porous Calcium phosphate cements. Mater Lett 2010; 64: 2028–2031.

15.

Lian

Jin

. Fabrication and in vitro evaluation of calcium phosphate combined with chitosan fibers for scaffold structures. J Bioact Compat Polym 2009; 24: 113–124.

16.

Girod Fullana

Ternet

Freche

. Controlled release properties and final macroporosity of a pectin microspheres-calcium phosphate composite bone cement. Acta Biomater 2010; 6: 2294–2300.

17.

Ishaug-Riley

Crane-Kruger

Yaszemski

. Three-dimensional culture of rat calvarial osteoblasts in porous biodegradable polymers. Biomaterials 1998; 19: 1405–1412.

18.

Ruhe

Boerman

Russel

. Controlled release of rhBMP-2 loaded poly(D-lactic-co-glycolic acid)/calcium phosphate cement composites in vivo. J Control Release 2005; 106: 162–171.

19.

Wang

. Improved injectability and in vitro degradation of a calcium phosphate cement containing poly (lactide-co-glycolide) microspheres. Acta Biomater 2008; 4: 1837–1845.

20.

Shive

Anderson

. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5–24.

21.

Body

. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002; 30: 75S–79S.

22.

Fan

Zhu

. Controllable release of salmon-calcitonin in injectable calcium phosphate cement modified by chitosan oligosaccharide and collagen polypeptide. J Mater Sci Mater Med 2007; 18: 2225–2231.

23.

Attawia

Uhrich

Botchwey

. In vitro bone biocompatibility of poly(anhydride-co-imides) containing pyromellitylimidoalanine. J Orthop Res 1996; 14: 445–454.

24.

Karageorgiou

Kaplan

. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials 2005; 26: 5474–5491.

25.

Wang

Feng

Cui

. The effects of S-chitosan on the physical properties of calcium phosphate cements. J Bioact Compat Polym 2003; 18: 45–57.

26.

Liu

Cheng

. Novel injectable calcium phosphate/chitosan composites for bone substitute materials. Acta Biomater 2006; 2: 557–565.

27.

. Mechanical and rheological properties and injectability of calcium phosphate cement containing poly(lactic-co-glycolic acid) microspheres. Mater Sci Eng C 2009; 29: 1901–1906.

28.

Kondo

Ogose

Tokunaga

. Osteoinduction with highly purified [beta]-tricalcium phosphate in dog dorsal muscles and the proliferation of osteoclasts before heterotopic bone formation. Biomaterials 2006; 27: 4419–4427.

29.

Zaffe

. Some considerations on biomaterials and bone. Micron 2005; 36: 583–592.

30.

Link

van den Dolder

van den Beucken

. Evaluation of the biocompatibility of calcium phosphate cement/PLGA microparticle composites. J Biomed Mater Res A 2008; 87: 760–769.

31.

Habibovic

Gbureck

Doillon

. Osteoconduction and osteoinduction of low-temperature 3D printed bioceramic implants. Biomaterials 2008; 29: 944–953.

32.

Agrawal

McKinney

Lanctot

. Effects of fluid flow on the in vitro degradation kinetics of biodegradable scaffolds for tissue engineering. Biomaterials 2000; 21: 2443–2452.

33.

Girod Fullana

Ternet

Freche

. Controlled release properties and final macroporosity of a pectin microspheres-calcium phosphate composite bone cement. Acta Biomaterials 2010; 6: 2294–2300.

34.

ISO 10993–5:1999. Biological evaluation of medical devices—Part 5: tests for in vitro cytotoxicity.

35.

Patel

Lyons

Hosking

. Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use. Drugs 1993; 46: 594–617.

36.

Sexton

Findlay

Martin

. Calcitonin. Curr Med Chem 1999; 6: 1067.

37.

Thamsborg

Jensen

Kollerup

. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996; 18: 207–212.

38.

Toth

Csupor

Meszaros

. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures–an open label study. Bone 2005; 36: 47–51.